Research programme: topical Syk kinase inhibitors - Ziarco
Latest Information Update: 28 Jan 2019
Price :
$50 *
At a glance
- Originator Pfizer
- Developer Ziarco
- Class Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Inflammation in United Kingdom (Topical)
- 16 Jul 2016 No recent reports of development identified for research development in Allergy in United Kingdom (Topical)
- 01 Dec 2014 Early research in Inflammation in United Kingdom (Topical)